Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials

  
AMD
Novartis' Brolucizumab Met Primary Endpoints In nAMD patients In Ph III Studies Versus Aflibercept • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business